keyword
MENU ▼
Read by QxMD icon Read
search

Radium 223

keyword
https://www.readbyqxmd.com/read/29137877/immune-analysis-of-radium-223-in-patients-with-metastatic-prostate-cancer
#1
Joseph W Kim, Min Sun Shin, Youna Kang, Insoo Kang, Daniel P Petrylak
BACKGROUND: Radium223 (Ra223) delivers high-energy radiation to osteoblastic metastasis of prostate cancer, resulting in irreparable double-stranded DNA damage. The effects of Ra223 on CD8+ T cell subsets in patients with prostate cancer is unknown. PATIENTS AND METHODS: Fifteen men with metastatic prostate cancer with clinical indication for Ra223 without any autoimmune or immune deficiency conditions were enrolled. Patients received a course of Ra223 50 kBq/kg...
October 24, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29134562/seom-clinical-guidelines-for-the-treatment-of-metastatic-prostate-cancer-2017
#2
J Cassinello, J Á Arranz, J M Piulats, A Sánchez, B Pérez-Valderrama, B Mellado, M Á Climent, D Olmos, J Carles, M Lázaro
Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma...
November 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29101113/treatment-of-advanced-prostate-cancer-a-review-of-current-therapies-and-future-promise
#3
Semini Sumanasuriya, Johann De Bono
Despite many recent advances in the therapy for metastatic castration-resistant prostate cancer (mCRPC), the disease remains incurable, although men suffering from this disease are living considerably longer. In this review, we discuss the current treatment options available for this disease, such as taxane-based chemotherapy, the novel hormone therapies abiraterone and enzalutamide, and treatments such as radium-223 and sipuleucel-T. We also highlight the need for ongoing research in this field, because, despite numerous recent advances, the prognosis for mCRPC remains poor...
November 3, 2017: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/29100167/early-identification-and-intervention-matters-a-comprehensive-review-of-current-evidence-and-recommendations-for-the-monitoring-of-bone-health-in-patients-with-cancer
#4
REVIEW
Thomas Brodowicz, Peyman Hadji, Daniela Niepel, Ingo Diel
Bone metastases are common in patients with advanced solid tumors, and many individuals experience debilitating skeletal-related events (SREs; e.g. pathologic fracture, hypercalcemia, radiotherapy or surgery to bone, and spinal cord compression). These events substantially affect disease outcomes, including survival and quality of life, and healthcare systems. Plain radiography is the most widely used imaging modality for the detection of bone metastases; skeletal scintigraphy, computed tomography, positron emission tomography and magnetic resonance imaging offer greater sensitivity but their use in routine practice is restricted by high costs and limited availability...
October 18, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29098556/selection-and-monitoring-of-patients-with-metastatic-castration-resistant-prostate-cancer-for-treatment-with-radium-223
#5
REVIEW
A Rodriguez-Vida, M D Torregrosa, Á Pinto, M Á Climent, D Olmos, J Carles
Despite the improvement provided by androgenic suppression in the treatment of prostate cancer, most of tumors develop resistance to castration. However, new therapies have demonstrated an increase in patient survival such as radium-223 (Ra-223), an alpha emitter and calcium mimetic with the capability of targeting osteoblastic metastatic lesions. According to results of the ALSYMPCA phase III trial, Ra-223 has demonstrated its activity by improving symptoms and survival of patients with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases, and no known visceral metastatic disease, without interfering with subsequent treatments...
November 2, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29079165/the-contemporary-use-of-radium-223-in-metastatic-castration-resistant-prostate-cancer
#6
Daniel Heinrich, Jasmin Bektic, Andries M Bergman, Orazio Caffo, Richard Cathomas, Kim N Chi, Gedske Daugaard, Daniel Keizman, Jon Kindblom, Gero Kramer, David Olmos, Aurelius Omlin, Srikala S Sridhar, Marcello Tucci, Inge van Oort, Sten Nilsson
Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for patients treated with radium-223 and best standard of care (BSoC) when compared with placebo and BSoC in the ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial. At that time, docetaxel was the standard first-line choice for patients with metastatic CRPC (mCRPC)...
September 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29055100/optical-emission-of-223-radium-in-vitro-and-in-vivo-preclinical-applications
#7
Federico Boschi, Francesco De Sanctis, Antonello E Spinelli
(223) Radium ((223) Ra) is widely used in Nuclear medicine to treat patients with osseous metastatic prostate cancer. In clinical practice (223) Ra cannot be imaged directly, however gamma photons produced by its short-lived daughter nuclides can be captured by conventional gamma cameras. In this work we show that (223) Ra and its short-lived daughter nuclides can be detected with optical imaging techniques. The light emission of (223) Ra was investigated in vitro using different setups in order to clarify the mechanism of light production...
October 20, 2017: Journal of Biophotonics
https://www.readbyqxmd.com/read/29046247/optimal-usage-of-radium-223-in-metastatic-castration-resistant-prostate-cancer
#8
REVIEW
Tai-Lung Cha, Tony Tong-Lin Wu, Nicholas John Vogelzang, Chao-Yuan Huang, Shu-Pin Huang, Chia-Chi Lin, Yen-Chuan Ou, See-Tong Pang, Daniel Heung-Yuan Shen, Wen-Jeng Wu, Wayne Yen-Hwa Chang
Radium-223 is a first-in-class α-emitting radiopharmaceutical that targets bone metastases associated with metastatic castration-resistant prostate cancer (mCRPC). In the pivotal phase III trial ALSYMPCA, radium-223 significantly increased overall survival (OS), compared with placebo (median 14.9 vs 11.3 months; hazard ratio 0.70; 95% CI 0.58-0.83; p < 0.001), in patients with mCRPC and symptomatic bone metastases-with a comparable safety profile. To optimize treatment outcomes, selection of appropriate patients is important...
November 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29027074/uptake-of-radium-223-dichloride-and-early-18-f-naf-pet-response-are-driven-by-baseline-18-f-naf-parameters-a-pilot-study-in-castration-resistant-prostate-cancer-patients
#9
Arthur Letellier, Alison C Johnson, Nicolas How Kit, Jean-François Savigny, Alain Batalla, Jean-Jacques Parienti, Nicolas Aide
PURPOSE: The purpose of this study is to identify predictive factors on baseline [(18)F]NaF positron emission tomography (PET)/computed tomography (CT) of early response to radium-223 dichloride after 3 cycles of treatment in metastatic castration-resistant prostate cancer patients. PROCEDURES: Analysis of 152 metastases was performed in six consecutive patients who underwent [(18)F]NaF PET/CT at baseline and for early monitoring after 3 cycles of radium-223 dichloride...
October 12, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/29026946/psma-targeted-radioligandtherapy-in-metastatic-castration-resistant-prostate-cancer-after-chemotherapy-abiraterone-and-or-enzalutamide-a-retrospective-analysis-of-overall-survival
#10
K Rahbar, M Boegemann, A Yordanova, M Eveslage, M Schäfers, M Essler, H Ahmadzadehfar
AIM: Our aim was to evaluate overall survival and parameters prognosticating longer survival in a large and homogeneous group of patients treated with (177)Lu-PSMA-617 radioligand therapy with heavily pretreated advanced metastatic castration resistant prostate cancer. METHODS: A total of 104 patients were treated with 351 cycles of (177)Lu-PSMA-617. Prostate specific antigen (PSA) changes after the first cycle of therapy were documented prior to a second cycle...
October 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29022046/-radium-223-dichloride-in-patients-with-castration-refractory-prostate-cancer
#11
REVIEW
B M Winter, F-C von Rundstedt, M-O Grimm
Since November 2013, the alpha emitter radium-223 dichloride (Alpharadin/Xofigo®) has been approved for the treatment of men with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. In the ASYMPCA clinical trial, radium-223 was shown to improve overall survival and to reduce the time to the first symptomatic skeletal event. The use of radium-223 was associated with a reduction of pain and an improvement of health-related quality of life compared to the placebo arm...
November 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28975586/impact-of-treatment-delay-in-radium-223-therapy-of-metastatic-castration-resistant-prostate-cancer-patients
#12
Marie Øbro Fosbøl, Peter Meidahl Petersen, Gedske Daugaard, Søren Holm, Andreas Kjaer, Jann Mortensen
BACKGROUND: Radium-223-dichloride (Ra-223) is an alpha-emitting, bone seeking radionuclide therapy approved for patients with metastatic castration-resistant prostate cancer (mCRPC). In the fall of 2014, a global temporary shortage of Ra-223 occurred for 2 months due to production irregularities. The aim of this study was to assess whether prolonged interval between Ra-223 cycles to non-disease related causes had a negative impact on clinical outcome of therapy. MATERIALS AND METHODS: Retrospective single-center study of mCRPC patients who initiated Ra-223 therapy in the period from March 2014 to February 2015...
October 3, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28966451/usefulness-of-radium-223-in-patients-with-bone-metastases
#13
REVIEW
Nishant Gupta, Arushi Devgan, Itisha Bansal, Thomas D Olsavsky, Shuo Li, Ahmed Abdelbaki, Yogesh Kumar
Castration-resistant prostate osseous metastases can be challenging to treat. There is a new era of clinical advancement with the Food and Drug Administration approval of radium-223 for use in these patients. Radium-223 is the only clinically used therapeutic radiopharmaceutical that emits alpha particles, making it extremely safe for therapeutic purposes for the patient as well as close contacts. This review discusses radium-223's mechanism of action, pharmacokinetics, indications, and safety profile, as well as findings of concluded clinical trials...
October 2017: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/28961839/re-treatment-with-radium-223-first-experience-from-an-international-open-label-phase-i-ii-study-in-patients-with-castration-resistant-prostate-cancer-and-bone-metastases
#14
O Sartor, D Heinrich, N Mariados, M J Méndez Vidal, D Keizman, C Thellenberg Karlsson, A Peer, G Procopio, S J Frank, K Pulkkanen, E Rosenbaum, S Severi, J M Trigo Perez, V Wagner, R Li, L T Nordquist
Background: Six radium-223 injections at 4-week intervals is indicated for patients with castration-resistant prostate cancer and symptomatic bone metastases. However, patients usually develop disease progression after initial treatment. This prospective phase I/II study assessed re-treatment safety and efficacy of up to six additional radium-223 injections. Patients and methods: Patients had castration-resistant prostate cancer and bone metastases and six initial radium-223 injections with no on-treatment bone progression; all had subsequent radiologic or clinical progression...
October 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28949940/optimal-use-of-radium-223-in-patients-with-metastatic-castration-resistant-prostate-cancer
#15
Daniel J George
No abstract text is available yet for this article.
September 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28930600/line-1-as-a-therapeutic-target-for-castration-resistant-prostate-cancer
#16
Nadine Houede, Pier Vincenzo Piazza, Philippe Pourquier
Prostate cancer is the third leading cause of death by cancer in men. Surgery or hormone deprivation usually contains the progression of the local forms of the disease. In metastatic situations, chemotherapy or second generation hormone therapies are used with an overall survival that never exceeds 36 months when tumors become resistant to castration. In the search for new alternatives, clinical trials with various classes of anticancer drugs have been performed, including chemotherapies, targeted therapies with kinase inhibitors, radium-223, or immunotherapies with somehow limited efficacy...
January 1, 2018: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28919714/radium-223-dichloride-for-prostate-cancer-treatment
#17
REVIEW
Emmanuel Deshayes, Mathieu Roumiguie, Constance Thibault, Philippe Beuzeboc, Florent Cachin, Christophe Hennequin, Damien Huglo, François Rozet, Diana Kassab-Chahmi, Xavier Rebillard, Nadine Houédé
Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo(®)) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone lesions. Radium-223 dichloride has been approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases, without known visceral metastases...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28866822/dutch-economic-value-of-radium-223-in-metastatic-castration-resistant-prostate-cancer
#18
Michel L Peters, Claudine de Meijer, Dirk Wyndaele, Walter Noordzij, Annemarie M Leliveld-Kors, Joan van den Bosch, Pieter H van den Berg, Agni Baka, Jennifer G Gaultney
BACKGROUND: The treatment of metastatic castration-resistant prostate cancer has changed with the introduction of radium-223, cabazitaxel, abiraterone and enzalutamide. To assess value for money, their cost effectiveness in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel from the Dutch societal perspective was investigated. METHODS: A cost-effectiveness analysis was conducted using efficacy, symptomatic skeletal-related event and safety data obtained from indirect treatment comparisons...
September 2, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28864632/radium-223-therapy-of-advanced-metastatic-castration-resistant-prostate-cancer-quantitative-assessment-of-skeletal-tumor-burden-for-prognostication-of-clinical-outcome-and-hematological-toxicity
#19
Marie Øbro Fosbøl, Peter Meidahl Petersen, Andreas Kjaer, Jann Mortensen
Aim: To investigate the prognostic value of quantitative assessment of skeletal tumor burden on bone scintigraphy (Bone Scan Index) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) receiving Radium-223-dichloride ((223)RaCl2). We hypothesize that Bone Scan Index (BSI) can serve as a prognostic biomarker of overall survival (OS) and hematological toxicity, as well as a tool for response assessment in patients with mCRPC treated with (223)RaCl2Methods: Retrospective study of the Danish cohort of mCRPC patients who received (223)RaCl2 therapy between March 2014 and October 2015 and for whom a baseline bone scintigraphy was available...
September 1, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28822315/applications-of-radon-and-radium-isotopes-to-determine-submarine-groundwater-discharge-and-flushing-times-in-todos-os-santos-bay-brazil
#20
Vanessa Hatje, Karina Kammer Attisano, Marcelo Friederichs Landim de Souza, Barbara Mazzilli, Joselene de Oliveira, Tamires de Araújo Mora, William C Burnett
Todos os Santos Bay (BTS) is the 2nd largest bay in Brazil and an important resource for the people of the State of Bahia. We made measurements of radon and radium in selected areas of the bay to evaluate if these tracers could provide estimates of submarine groundwater discharge (SGD) and flushing times of the Paraguaçu Estuary and BTS. We found that there were a few areas along the eastern and northeastern shorelines that displayed relatively high radon and low salinities, indicating possible sites of enhanced SGD...
November 2017: Journal of Environmental Radioactivity
keyword
keyword
34989
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"